TY  - JOUR
PY  - 2020//
TI  - Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products
JO  - Therapeutic advances in psychopharmacology
A1  - Chesney, Edward
A1  - McGuire, Philip
A1  - Freeman, Tom P.
A1  - Strang, John
A1  - Englund, Amir
SP  - e2045125320954992
EP  - e2045125320954992
VL  - 10
IS  - 
N2  - Over the past 5 years, public interest in the potential health benefits of cannabidiol (CBD) has increased exponentially, and a wide range of over-the-counter (OTC) preparations of CBD are now available. A substantial proportion of the population appears to have used these products, yet the extent to which they are effective or safe is unclear. We reviewed the evidence for whether CBD has significant pharmacological and symptomatic effects at the doses typically found in OTC preparations. We found that most of the evidence for beneficial effects is derived from studies of pure, pharmaceutical grade CBD at relatively high doses. Relatively few studies have examined the effect of OTC CBD preparations, or of CBD at low doses. Thus, at present, there is little evidence that OTC CBD products have health benefits, and their safety has not been investigated. Controlled trials of OTC and low-dose CBD preparations are needed to resolve these issues.<p />  <p>Language: en</p>
LA  - en
SN  - 2045-1253
UR  - http://dx.doi.org/10.1177/2045125320954992
ID  - ref1
ER  -